

May 1, 2018



OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories

MIAMI, May 01, 2018 (GLOBE NEWSWIRE) -- **OPKO Health, Inc.** (NASDAQ:OPK) today announced the appointment of Geoff Monk as General Manager with overall responsibility for BioReference Laboratories (BRL), an OPKO Health company and the third largest clinical laboratory in the United States. Mr. Monk brings to BRL more than 20 years of operational, business strategy and technical experience. Previously, Mr. Monk worked as Managing Director of the New York and New Jersey unit of Quest Diagnostics, with P&L responsibility for Quest's largest and most profitable business unit.

"Geoff has built an enviable track record of operational excellence and has delivered consistently impressive results. We are delighted to have Geoff join our team," stated Phillip Frost, Chairman and Chief Executive Officer of OPKO Health.

Mr. Monk holds an MA in engineering from Cambridge University.

About OPKO Health, Inc.

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for secondary hyperparathyroidism in stage 3 and 4 chronic kidney disease patients with vitamin D insufficiency (launched in November 2016), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic Hypertrophy), OPK88002, a NK-1 antagonist to treat pruritus (itching) in dialysis patients, and OPK88001, a proprietary oligonucleotide to treat Dravet Syndrome. In addition, the Company is advancing its CTP technology, which includes a long acting hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer). OPKO also has production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

CONTACTS:

Company

OPKO Health, Inc.

David Malina, 305-575-4100

Investor Relations

Investors

LHA Investor Relations

Miriam Weber Miller, 212-838-3777

MMiller@lhai.com

or

Bruce Voss, 310-691-7100

bvoss@lhai.com



Source: OPKO Health, Inc.